Press Releases

Date Title  
Toggle Summary Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
- Company Enters into Commercial Supply Agreement for AR101 - BRISBANE, Calif. --(BUSINESS WIRE)--May 16, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has been informed by the U.S.
Toggle Summary Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Aug. 21, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of
Toggle Summary Aimmune Statement on Institute for Clinical and Economic Review (ICER) Final Report on AR101 for Peanut Allergy
Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 immunotherapy can deliver to the peanut allergy community BRISBANE, Calif. --(BUSINESS WIRE)--Jul. 11, 2019-- Aimmune Therapeutics (Nasdaq: AIMT), a biopharmaceutical company
Toggle Summary Aimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 13, 2019-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S.
Toggle Summary Aimmune Submits Marketing Authorization Application to European Medicines Agency for AR101 for Peanut Allergy
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 28, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency
Toggle Summary Aimmune Therapeutics and KKR Enter into $170M Loan Agreement to Fund AR101 Commercialization and Pipeline Advancement
BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 4, 2019-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has entered into a $170 million loan agreement with an affiliate of KKR, a leading
Toggle Summary Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
— Nestlé Health Science to Make Investment through the Purchase of Nearly 7.6 Million Shares of Aimmune Stock at $19.20 per Share — — Companies Enter into Strategic Collaboration Agreement Designed to Enable the Successful Development and Commercialization of Innovative Food Allergy Therapies — —
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics Announces Additional Equity Investment by Nestlé Health Science
— Nestlé Health Science to Invest $98 Million in Aimmune through the Purchase of 3.24 Million Shares of Aimmune Stock at $30.27 per Share — — Companies Extend Existing Strategic Collaboration Agreement Focused on Offering Innovative Food Allergy Therapies — — Nestlé Health Science CEO Greg Behar
Toggle Summary Aimmune Therapeutics Announces Appointment of Dr. Brett Haumann to Board of Directors
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 2, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that Brett Haumann , M.B.B.Ch., M.B.A., has joined the Aimmune Board of Directors,